GXE Stock Overview
A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €23.76 |
| 52 Week High | €38.58 |
| 52 Week Low | €21.86 |
| Beta | 0.060 |
| 11 Month Change | -13.60% |
| 3 Month Change | 3.48% |
| 1 Year Change | -29.22% |
| 33 Year Change | -44.51% |
| 5 Year Change | -86.36% |
| Change since IPO | 232.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| GXE | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.0% | 0.8% | -1.3% |
| 1Y | -29.2% | -17.5% | 7.4% |
Return vs Industry: GXE underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: GXE underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| GXE volatility | |
|---|---|
| GXE Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GXE has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GXE's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 683 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
| GXE fundamental statistics | |
|---|---|
| Market cap | €1.58b |
| Earnings (TTM) | -€60.61m |
| Revenue (TTM) | €260.09m |
6.1x
P/S Ratio-26.0x
P/E RatioIs GXE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GXE income statement (TTM) | |
|---|---|
| Revenue | €260.09m |
| Cost of Revenue | €331.48m |
| Gross Profit | -€71.38m |
| Other Expenses | -€10.77m |
| Earnings | -€60.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -27.45% |
| Net Profit Margin | -23.30% |
| Debt/Equity Ratio | 0% |
How did GXE perform over the long term?
See historical performance and comparison